aTyr Pharma, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 14.76 million compared to USD 7.52 million a year ago. Basic loss per share from continuing operations was USD 0.25 compared to USD 0.26 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.69 USD | -1.74% | +4.97% | +19.86% |
02/05 | ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
02/05 | Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.86% | 115M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- LIFE Stock
- News aTyr Pharma, Inc.
- ATyr Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023